Connect with us


5 Penny Stocks To Buy For Under $5 Right Now

Which penny stocks are on your watch list right now?
The post 5 Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |



Are These Penny Stocks On Your December Watch List?

If you’re making a penny stocks watch list, you’re not alone. Right now, there are hundreds of penny stocks to choose from across a large variety of industries. As a result, finding the best penny stocks to buy has never been easier. But, in 2021, all traders need to consider plenty of factors before investing. This includes the pandemic, inflation, and the most recent variant of Covid, Omicron.

[Read More] How to Make Money With Penny Stocks And the Omicron Variant

 Because of these external factors, trading penny stocks is all about knowing what’s coming next. For this reason, staying up to date with the latest news and events is crucial to making money with penny stocks. With all of that in mind, let’s take a look at five penny stocks that should be on your list this month. 

Penny Stocks to Buy For Under $5

  1. Liquidia Corporation (NASDAQ: LQDA)
  2. Stran & Co. Inc. (NASDAQ: STRN)
  3. Farmmi Inc. (NASDAQ: FAMI
  4. Denison Mines Corp. (NYSE: DNN
  5. Ardelyx Inc. (NASDAQ: ARDX)

Penny Stocks To Buy [or avoid] 1. Liquidia Corporation (NASDAQ: LQDA)

Liquidia Corporation develops treatments for hypertension and uses its PRINT technology platform to do so. The company’s YUTREPIA, an inhaled powder for pulmonary arterial hypertension, was recently granted tentative approval by the FDA.

The company specializes in developing treatments for hypertension and utilizes its PRINT technology to advance its portfolio of candidates. Liquidia developed YUTREPIA, which is an inhaled powder user for treating pulmonary arterial hypertension. Now the next steps include pre-commercial launch activities.

Adding to the optimism surrounding Liquidia’s commercial launch were several insider buying within the last 30 days. These included Director Arthur Kirsch and General Council Russell Schundler. Collectively, they bought more than 130,000 shares at average prices ranging from $4.21 to $4.24.

While there haven’t been any new updates regarding Liquidia’s YUTREPIA pre-commercial activities, shares of LQDA stock started climbing late in the week last week. Considering the broader markets selling off, this contrary move in the stock market last week could be something to pay attention to heading into the start of the week ahead.

[Read More] Penny Stocks To Buy For A Short Squeeze? 5 To Watch Now

2. Stran & Co. Inc. (NASDAQ: STRN)

The recent IPO of Stran & Co has been something to watch for most of November. Following a model open on its market debut, STRN stock mounted a multi-day, 96% move to highs of over $6. As the market focused on Stran’s branding & marketing platform, it helped the penny stock gain attention during the final quarter of the year. Stran has a long-standing track record for providing many Fortune 500 companies marketing programs that include everything from loyalty & incentives to branded merchandise and sponsorships.

One of the interesting things to note is the company’s current share structure. Stran was able to raise sufficient money through its IPO. But, if you look at the STRN stock profile page, you’ll see something interesting. Its current outstanding share count sits below 20 million shares. If you’ve read some of our introductory articles, you know that the Float will never be more than the Outstanding, and therefore, STRN stock has gotten wrapped into the low float penny stock category.

This might also explain the days when it saw a bit more volatility than other companies in the marketing and branding category. Whether or not this plays a role heading into the rest of the month is to be seen. However, after its IPO hangover sell-off, STRN stock has bounced back stronger, with seven consecutive sessions closing higher than it opened.

best penny stocks to buy under $5 Stran & Co Inc. STRN stock chart

3. Farmmi Inc. (NASDAQ: FAMI)

Farmmi Inc. is a penny stock that has seen heightened attention in the past few weeks. As a trending penny stock, Farmmi has continued to see high volume during that time. If you’re not familiar, FAMI is an agricultural company based in China. Farmmi is involved in the processing and selling of an extensive range of agricultural products. Currently, the company offers Mu Er mushrooms, shiitake, and various other edible fungi products. The company also exports these edible fungi products to Israel, Canada, and more. These products are sold to restaurants, specialty stores, cafeterias, and more.

On November 15th, the company signed a new product order. Its subsidiary Zhejiang Fammi Biotechnology Co. Ltd., won a product order from a customer in Vancouver, Canada, for its dried black fungus product. This is one of many product orders that the company has signed into in the past few months, which is exciting for investors to consider. 

“We continue to execute on our multi-pronged growth strategy, as we leverage our brand, premium agriculture product line, and global supply chain relationships. We have benefited from steady growth in 2021 and expect year over year growth compared to 2020, with 2022 even better based on customer demand indications.”

Ms. Yefang Zhang, the Chairwoman, and CEO of Farmmi

The company received an extension on its NASDAQ minimum bid price requirement in other recent news. Noting this current info, will FAMI be on your list of penny stocks to watch?


4. Denison Mines Corp. (NYSE: DNN)

Denison Mines Corp. is a penny stock that has shot up by over 110% in the past YTD period and more than 250% in the past twelve months. These are staggering gains that reflect both Denison as a company and the uranium mining industry. For some context, Denison is a mining company that pursues uranium developments. The development company owns a 95% stake in the Wheeler uranium project, located in northern Saskatchewan’s Athabasca Basin. It’s worth noting that we’ve discussed Denison many times in the past year due to its trending nature. 

[Read More] 3 Biotech Penny Stocks To Watch With The Stock Market Down Today

On December 2nd, the company announced the adoption of an Indigenous Peoples Policy or IPP. This was approved by the Board of Directors and reflects the company’s recognition of the important role of Canadian business while reconciling with Indigenous peoples in the country. Additionally, this is in line with Denison’s commitment to take action towards advancing reconciliation. This is important to the company as it operates in various locations in Canada that are in the traditional territory of Indigenous peoples.

“I believe Industry has an important role to play in acknowledging, and building awareness of, the history of Indigenous people in Canada and the critical importance of pursuing the objectives of reconciliation. As such, the adoption of an Indigenous Peoples Policy is a notable step in our Company’s journey to bring reconciliation to the forefront of what we do and how we do it.”

The President and CEO of Denison, David Cates

Noting its recent advancements, will DNN stock make your penny stocks watchlist?


5. Ardelyx Inc. (NASDAQ: ARDX)

Ardelyx Inc. is a biotech penny stock that has made substantial gains in the past few trading days. Over the last five, shares of ARDX stock have shot up by a tremendous 60%. Ardelyx is a company that creates treatments for kidney and cardiorenal diseases. The company is involved in the development and sale of these medicines. Its lead candidate is tenapanor, which completed Phase 3 clinical trials to treat patients with irritable bowel syndrome with constipation. Ardelyx also develops RDX013, which is in Phase 2 clinical trial to treat hyperkalemia patients.

On November 30th, the company announced its plans to launch IBSRELA. IBSRELA is Ardelyx’s approved treatment for IBS with constipation in adults. The company intends on launching this approved treatment in the second quarter of 2022. Ardelyx is still pursuing the approval of tenapanor for hyperphosphatemia through the formal dispute resolution process with the FDA at the moment as well.

“Over the last five years, the IBS-C market has grown to be sizeable and concentrated, with 9,000 high-writing physicians accounting for approximately 50% of the almost five million prescriptions written annually for drugs indicated for the treatment of IBS-C. This market is ripe for the entry of a novel therapeutic option like IBSRELA, as existing therapies do not adequately address all patient treatment needs.” 

President and CEO of Ardelyx, Mike Robb

In the last month, ARDX stock has increased significantly. Most of this momentum started on November 30th and has carried through to December 2nd. Noting this, will ARDX be on your list of penny stocks to watch.


Which Penny Stocks Are You Watching Right Now?

In 2021, hundreds of penny stocks could have value, but it takes dedication to understand how certain events can impact the penny stocks on your list to make money with small caps.

Best Penny Stocks to Buy Right Now? 3 to Watch As December Begins

As a result, making a list of the best penny stocks to buy takes research and a thorough trading strategy. With all of this in mind, which penny stocks are you watching right now?

The post 5 Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Home buyers must now navigate higher mortgage rates and prices

Rates under 4% came and went during the Covid pandemic, but home prices soared. Here’s what buyers and sellers face as the housing season ramps up.



Springtime is spreading across the country. You can see it as daffodil, camellia, tulip and other blossoms start to emerge. 

You can also see it in the increasing number of for sale signs popping up in front of homes, along with the painting, gardening and general sprucing up as buyers get ready to sell. 

Which leads to two questions: 

  • How is the real estate market this spring? 
  • Where are mortgage rates? 

What buyers and sellers face

The housing market is bedeviled with supply shortages, high prices and slow sales.

Mortgage rates are still high and may limit what a buyer can offer and a seller can expect.  

Related: Analyst warns that a TikTok ban could lead to major trouble for Apple, Big Tech

And there's a factor not expected that may affect the sales process. Fixed commission rates on home sales are going away in July.

Reports this week and in a week will make the situation clearer for buyers and sellers. 

The reports are:

  • Housing starts from the U.S. Commerce Department due Tuesday. The consensus estimate is for a seasonally adjusted rate of about 1.4 million homes. These would include apartments, both rentals and condominiums. 
  • Existing home sales, due Thursday from the National Association of Realtors. The consensus estimate is for a seasonally adjusted sales rate of about 4 million homes. In 2023, some 4.1 million homes were sold, the worst sales rate since 1995. 
  • New-home sales and prices, due Monday from the Commerce Department. Analysts are expecting a sales rate of 661,000 homes (including condos), up 1.5% from a year ago.

Here is what buyers and sellers need to know about the situation. 

Mortgage rates will stay above 5% 

That's what most analysts believe. Right now, the rate on a 30-year mortgage is between 6.7% and 7%. 

Rates peaked at 8% in October after the Federal Reserve signaled it was done raising interest rates.

The Freddie Mac Primary Mortgage Market Survey of March 14 was at 6.74%. 

Freddie Mac buys mortgages from lenders and sells securities to investors. The effect is to replenish lenders' cash levels to make more loans. 

A hotter-than-expected Producer Price Index released that day has pushed quotes to 7% or higher, according to data from Mortgage News Daily, which tracks mortgage markets.

Home buyers must navigate higher mortgage rates and prices this spring.


On a median-priced home (price: $380,000) and a 20% down payment, that means a principal and interest rate payment of $2,022. The payment  does not include taxes and insurance.

Last fall when the 30-year rate hit 8%, the payment would have been $2,230. 

In 2021, the average rate was 2.96%, which translated into a payment of $1,275. 

Short of a depression, that's a rate that won't happen in most of our lifetimes. 

Most economists believe current rates will fall to around 6.3% by the end of the year, maybe lower, depending on how many times the Federal Reserve cuts rates this year. 

If 6%, the payment on our median-priced home is $1,823.

But under 5%, absent a nasty recession, fuhgettaboutit.

Supply will be tight, keeping prices up

Two factors are affecting the supply of homes for sale in just about every market.

First: Homeowners who had been able to land a mortgage at 2.96% are very reluctant to sell because they would then have to find a home they could afford with, probably, a higher-cost mortgage.

More economic news:

Second, the combination of high prices and high mortgage rates are freezing out thousands of potential buyers, especially those looking for homes in lower price ranges.

Indeed, The Wall Street Journal noted that online brokerage Redfin said only about 20% of homes for sale in February were affordable for the typical household.

And here mortgage rates can play one last nasty trick. If rates fall, that means a buyer can afford to pay more. Sellers and their real-estate agents know this too, and may ask for a higher price. 

Covid's last laugh: An inflation surge

Mortgage rates jumped to 8% or higher because since 2022 the Federal Reserve has been fighting to knock inflation down to 2% a year. Raising interest rates was the ammunition to battle rising prices.

In June 2022, the consumer price index was 9.1% higher than a year earlier. 

The causes of the worst inflation since the 1970s were: 

  • Covid-19 pandemic, which caused the global economy to shut down in 2020. When Covid ebbed and people got back to living their lives, getting global supply chains back to normal operation proved difficult. 
  • Oil prices jumped to record levels because of the recovery from the pandemic recovery and Russia's invasion of Ukraine.

What the changes in commissions means

The long-standing practice of paying real-estate agents will be retired this summer, after the National Association of Realtors settled a long and bitter legal fight.

No longer will the seller necessarily pay 6% of the sale price to split between buyer and seller agents.

Both sellers and buyers will have to negotiate separately the services agents have charged for 100 years or more. These include pre-screening properties, writing sales contracts, and the like. The change will continue a trend of adding costs and complications to the process of buying or selling a home.

Already, interest rates are a complication. In addition, homeowners insurance has become very pricey, especially in communities vulnerable to hurricanes, tornadoes, and forest fires. Florida homeowners have seen premiums jump more than 102% in the last three years. A policy now costs three times more than the national average.

Related: Veteran fund manager picks favorite stocks for 2024


Read More

Continue Reading


Mistakes Were Made

Mistakes Were Made

Authored by C.J.Hopkins via The Consent Factory,

Make fun of the Germans all you want, and I’ve certainly done that…



Mistakes Were Made

Authored by C.J.Hopkins via The Consent Factory,

Make fun of the Germans all you want, and I’ve certainly done that a bit during these past few years, but, if there’s one thing they’re exceptionally good at, it’s taking responsibility for their mistakes. Seriously, when it comes to acknowledging one’s mistakes, and not rationalizing, or minimizing, or attempting to deny them, and any discomfort they may have allegedly caused, no one does it quite like the Germans.

Take this Covid mess, for example. Just last week, the German authorities confessed that they made a few minor mistakes during their management of the “Covid pandemic.” According to Karl Lauterbach, the Minister of Health, “we were sometimes too strict with the children and probably started easing the restrictions a little too late.” Horst Seehofer, the former Interior Minister, admitted that he would no longer agree to some of the Covid restrictions today, for example, nationwide nighttime curfews. “One must be very careful with calls for compulsory vaccination,” he added. Helge Braun, Head of the Chancellery and Minister for Special Affairs under Merkel, agreed that there had been “misjudgments,” for example, “overestimating the effectiveness of the vaccines.”

This display of the German authorities’ unwavering commitment to transparency and honesty, and the principle of personal honor that guides the German authorities in all their affairs, and that is deeply ingrained in the German character, was published in a piece called “The Divisive Virus” in Der Spiegel, and immediately widely disseminated by the rest of the German state and corporate media in a totally organic manner which did not in any way resemble one enormous Goebbelsian keyboard instrument pumping out official propaganda in perfect synchronization, or anything creepy and fascistic like that.

Germany, after all, is “an extremely democratic state,” with freedom of speech and the press and all that, not some kind of totalitarian country where the masses are inundated with official propaganda and critics of the government are dragged into criminal court and prosecuted on trumped-up “hate crime” charges.

OK, sure, in a non-democratic totalitarian system, such public “admissions of mistakes” — and the synchronized dissemination thereof by the media — would just be a part of the process of whitewashing the authorities’ fascistic behavior during some particularly totalitarian phase of transforming society into whatever totalitarian dystopia they were trying to transform it into (for example, a three-year-long “state of emergency,” which they declared to keep the masses terrorized and cooperative while they stripped them of their democratic rights, i.e., the ones they hadn’t already stripped them of, and conditioned them to mindlessly follow orders, and robotically repeat nonsensical official slogans, and vent their impotent hatred and fear at the new “Untermenschen” or “counter-revolutionaries”), but that is obviously not the case here.

No, this is definitely not the German authorities staging a public “accountability” spectacle in order to memory-hole what happened during 2020-2023 and enshrine the official narrative in history. There’s going to be a formal “Inquiry Commission” — conducted by the same German authorities that managed the “crisis” — which will get to the bottom of all the regrettable but completely understandable “mistakes” that were made in the heat of the heroic battle against The Divisive Virus!

OK, calm down, all you “conspiracy theorists,” “Covid deniers,” and “anti-vaxxers.” This isn’t going to be like the Nuremberg Trials. No one is going to get taken out and hanged. It’s about identifying and acknowledging mistakes, and learning from them, so that the authorities can manage everything better during the next “pandemic,” or “climate emergency,” or “terrorist attack,” or “insurrection,” or whatever.

For example, the Inquiry Commission will want to look into how the government accidentally declared a Nationwide State of Pandemic Emergency and revised the Infection Protection Act, suspending the German constitution and granting the government the power to rule by decree, on account of a respiratory virus that clearly posed no threat to society at large, and then unleashed police goon squads on the thousands of people who gathered outside the Reichstag to protest the revocation of their constitutional rights.

Once they do, I’m sure they’ll find that that “mistake” bears absolutely no resemblance to the Enabling Act of 1933, which suspended the German constitution and granted the government the power to rule by decree, after the Nazis declared a nationwide “state of emergency.”

Another thing the Commission will probably want to look into is how the German authorities accidentally banned any further demonstrations against their arbitrary decrees, and ordered the police to brutalize anyone participating in such “illegal demonstrations.”

And, while the Commission is inquiring into the possibly slightly inappropriate behavior of their law enforcement officials, they might want to also take a look at the behavior of their unofficial goon squads, like Antifa, which they accidentally encouraged to attack the “anti-vaxxers,” the “Covid deniers,” and anyone brandishing a copy of the German constitution.

Come to think of it, the Inquiry Commission might also want to look into how the German authorities, and the overwhelming majority of the state and corporate media, accidentally systematically fomented mass hatred of anyone who dared to question the government’s arbitrary and nonsensical decrees or who refused to submit to “vaccination,” and publicly demonized us as “Corona deniers,” “conspiracy theorists,” “anti-vaxxers,” “far-right anti-Semites,” etc., to the point where mainstream German celebrities like Sarah Bosetti were literally describing us as the inessential “appendix” in the body of the nation, quoting an infamous Nazi almost verbatim.

And then there’s the whole “vaccination” business. The Commission will certainly want to inquire into that. They will probably want to start their inquiry with Karl Lauterbach, and determine exactly how he accidentally lied to the public, over and over, and over again …

And whipped people up into a mass hysteria over “KILLER VARIANTS” …



And so on. I could go on with this all day, but it will be much easier to just refer you, and the Commission, to this documentary film by Aya Velázquez. Non-German readers may want to skip to the second half, unless they’re interested in the German “Corona Expert Council” …

Look, the point is, everybody makes “mistakes,” especially during a “state of emergency,” or a war, or some other type of global “crisis.” At least we can always count on the Germans to step up and take responsibility for theirs, and not claim that they didn’t know what was happening, or that they were “just following orders,” or that “the science changed.”

Plus, all this Covid stuff is ancient history, and, as Olaf, an editor at Der Spiegel, reminds us, it’s time to put the “The Divisive Pandemic” behind us …

… and click heels, and heil the New Normal Democracy!

Tyler Durden Sat, 03/16/2024 - 23:20

Read More

Continue Reading


“Extreme Events”: US Cancer Deaths Spiked In 2021 And 2022 In “Large Excess Over Trend”

"Extreme Events": US Cancer Deaths Spiked In 2021 And 2022 In "Large Excess Over Trend"

Cancer deaths in the United States spiked in 2021…



"Extreme Events": US Cancer Deaths Spiked In 2021 And 2022 In "Large Excess Over Trend"

Cancer deaths in the United States spiked in 2021 and 2022 among 15-44 year-olds "in large excess over trend," marking jumps of 5.6% and 7.9% respectively vs. a rise of 1.7% in 2020, according to a new preprint study from deep-dive research firm, Phinance Technologies.

Algeria, Carlos et. al "US -Death Trends for Neoplasms ICD codes: C00-D48, Ages 15-44", ResearchGate, March. 2024 P. 7

Extreme Events

The report, which relies on data from the CDC, paints a troubling picture.

"We show a rise in excess mortality from neoplasms reported as underlying cause of death, which started in 2020 (1.7%) and accelerated substantially in 2021 (5.6%) and 2022 (7.9%). The increase in excess mortality in both 2021 (Z-score of 11.8) and 2022 (Z-score of 16.5) are highly statistically significant (extreme events)," according to the authors.

That said, co-author, David Wiseman, PhD (who has 86 publications to his name), leaves the cause an open question - suggesting it could either be a "novel phenomenon," Covid-19, or the Covid-19 vaccine.

"The results indicate that from 2021 a novel phenomenon leading to increased neoplasm deaths appears to be present in individuals aged 15 to 44 in the US," reads the report.

The authors suggest that the cause may be the result of "an unexpected rise in the incidence of rapidly growing fatal cancers," and/or "a reduction in survival in existing cancer cases."

They also address the possibility that "access to utilization of cancer screening and treatment" may be a factor - the notion that pandemic-era lockdowns resulted in fewer visits to the doctor. Also noted is that "Cancers tend to be slowly-developing diseases with remarkably stable death rates and only small variations over time," which makes "any temporal association between a possible explanatory factor (such as COVID-19, the novel COVID-19 vaccines, or other factor(s)) difficult to establish."

That said, a ZeroHedge review of the CDC data reveals that it does not provide information on duration of illness prior to death - so while it's not mentioned in the preprint, it can't rule out so-called 'turbo cancers' - reportedly rapidly developing cancers, the existence of which has been largely anecdotal (and widely refuted by the usual suspects).

While the Phinance report is extremely careful not to draw conclusions, researcher "Ethical Skeptic" kicked the barn door open in a Thursday post on X - showing a strong correlation between "cancer incidence & mortality" coinciding with the rollout of the Covid mRNA vaccine.

Phinance principal Ed Dowd commented on the post, noting that "Cancer is suddenly an accelerating growth industry!"


Bottom line - hard data is showing alarming trends, which the CDC and other agencies have a requirement to explore and answer truthfully - and people are asking #WhereIsTheCDC.

We aren't holding our breath.

Wiseman, meanwhile, points out that Pfizer and several other companies are making "significant investments in cancer drugs, post COVID."


We've featured several of Phinance's self-funded deep dives into pandemic data that nobody else is doing. If you'd like to support them, click here.


Tyler Durden Sat, 03/16/2024 - 16:55

Read More

Continue Reading